Meeting
2023 ASCO Annual Meeting
Predicting role of circulating tumor DNA and blood-based tumor mutational burden in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with toripalimab: Exploratory analyses from a phase II trial (EC-CRT-001).
Authors
Baoqing Chen
Sun Yat-sen University Cancer Center, Guangzhou, China
Baoqing Chen , Shi-Liang Liu , Qiaoqiao Li , Mengzhong Liu , Hong Yang , Mian Xi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT04005170
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4056)
DOI
10.1200/JCO.2023.41.16_suppl.4056
Abstract #
4056
Poster Bd #
377
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
First Author: Manabu Muto
Poster
2023 ASCO Annual Meeting
Induction chemotherapy plus definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: Long-term results and exploratory analyses of a randomized controlled trial.
First Author: Mian Xi
Poster
2024 ASCO Genitourinary Cancers Symposium
Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.
First Author: Yijun Shen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Ezabenlimab (BI 754091) plus modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) followed by chemoradiotherapy (CRT) in patients (pts) with stage III squamous cell anal carcinoma (SCCA): Early efficacy endpoint results from the phase II INTERACT-ION study.
First Author: Stefano Kim